Rate My Professor Alex Cristino

Dr. Alex Cristino is a Senior Lecturer in Bioinformatics in the ESC - Biomedical section of the School of Environment and Science at Griffith University. He holds the position of Research Leader in the Functional Genomics and Systems Biology Lab at the Griffith Institute for Drug Discovery. Cristino obtained his PhD in Bioinformatics from the University of Queensland in 2007, followed by postdoctoral training at the University of Cambridge, United Kingdom. Earlier in his career, he worked at the Queensland Brain Institute and the Institute for Molecular Bioscience at the University of Queensland. His research centers on developing innovative systems-based approaches that integrate computational predictions with rigorous experimental validation to identify novel therapeutic targets for complex diseases, spanning neurodevelopment, neurodegeneration, cancer, infectious diseases, and rare disorders such as Hereditary Spastic Paraplegia. Cristino leads bioinformatics and systems biology projects aimed at advancing drug discovery, including stem cell models for schizophrenia treatment, molecular mechanisms in blood cancer immune responses, and pathways inhibiting prostate cancer spread.

Cristino has made significant contributions to the field through key publications, including 'Caveolin-1-driven membrane remodelling regulates mood-associated cellular targets and acute stress responsiveness' (Clinical and Translational Medicine, 2021), 'The IRE1α-endonuclease regulates PD-1 expression through a novel XBP1/miRNA-34a axis within Natural Killer cells' (2023), and studies on EBV microRNA targeting immune checkpoints. He received the 2023 Australasian Neuroscience Society Illumina Research Award and the Griffith Sciences Pro Vice Chancellor's Excellence Award for Health and Safety Initiative/Leadership Team. At Griffith, he convenes the course Applied Bioinformatics (3030NSC) and supervises PhD projects, such as developing RNA-based treatments to enhance immune responses against cancers. His interdisciplinary collaborations, including with Mater Research and QIMR Berghofer, underscore his impact on precision medicine, single-cell omics platforms, and therapeutic innovation for unmet medical needs.